Scientists at the University of Virginia say they may be one step closer to stopping a rare and deadly disease that hardens ...
UVA researcher Blandine Baffert, working in the lab of UVA Health’s Sanja Arandjelovic and collaborating with researchers in ...
Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
By determining the structure of the deposits responsible for transthyretin amyloidosis through a simple skin biopsy, scientists at UNIGE are paving the way for a new diagnostic method for ...
A lack of understanding about what scabies is and how it’s treated could be behind the United Kingdom’s sudden spike in cases ...
But there’s one side effect that’s well established but little known and still puzzling to doctors: the “keto rash” or prurigo pigmentosa. This rash fits the man’s case perfectly—red, raised, itchy ...
Emily McAllister was diagnosed with Stevens-Johnson syndrome (SJS), a rare and debilitating skin disease that resulted in the ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella’s QTORIN rapamycin platform demonstrates high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results